Dianthus Therapeutics (Dianthus Therapeutics) Total Liabilities : $9.78 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Total Liabilities?

Dianthus Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $9.78 Mil.

Dianthus Therapeutics's quarterly Total Liabilities declined from Sep. 2023 ($14.08 Mil) to Dec. 2023 ($10.54 Mil) and declined from Dec. 2023 ($10.54 Mil) to Mar. 2024 ($9.78 Mil).

Dianthus Therapeutics's annual Total Liabilities declined from Dec. 2021 ($26.70 Mil) to Dec. 2022 ($9.45 Mil) but then increased from Dec. 2022 ($9.45 Mil) to Dec. 2023 ($10.54 Mil).

Dianthus Therapeutics Total Liabilities Historical Data

The historical data trend for Dianthus Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Total Liabilities Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Liabilities

26.70

9.45

10.54

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial			9.45	-	14.08	10.54	9.78

Dianthus Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Dianthus Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	9.631	+	(0.168	+	-1.1102230246252E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.736	+	0)
	=	10.54

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	179.405	-	168.87
	=	10.54

Dianthus Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.959	+	(0.097	+	7.7715611723761E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.719	+	0)
	=	9.78

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	382.462	-	372.687
	=	9.77

Dianthus Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023